Detalhe da pesquisa
1.
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma.
Blood
; 143(7): 597-603, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048552
2.
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.
Blood
; 142(18): 1518-1528, 2023 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37506339
3.
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
Blood
; 137(1): 49-60, 2021 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32693406
4.
Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients.
Haematologica
; 108(10): 2753-2763, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37102598
5.
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.
Haematologica
; 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38031761
6.
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma.
Blood
; 136(2): 199-209, 2020 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32325491
7.
5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics.
Eur J Haematol
; 109(6): 755-764, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36063368
8.
Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease.
Blood
; 133(25): 2664-2668, 2019 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31010846
9.
Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain.
Biol Blood Marrow Transplant
; 26(8): 1534-1542, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32068094
10.
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.
Blood
; 132(1): 49-58, 2018 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29666118
11.
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries.
Br J Haematol
; 181(3): 350-359, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29611196
12.
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.
Blood
; 127(9): 1151-62, 2016 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-26668134
13.
Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?
Blood
; 138(19): 1901-1905, 2021 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34329372
14.
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
Blood
; 127(25): 3165-74, 2016 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-27118453
15.
Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.
Blood
; 127(4): 420-5, 2016 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26500339
16.
Fatigue- and health-related quality-of-life in anemic patients with lymphoma or multiple myeloma.
Support Care Cancer
; 26(4): 1253-1264, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29116407
17.
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.
Int J Mol Sci
; 18(4)2017 Apr 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-28420120
18.
Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes.
Genes Chromosomes Cancer
; 55(4): 322-7, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26690722
19.
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
Lancet Oncol
; 17(8): 1127-1136, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27402145
20.
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.
N Engl J Med
; 369(5): 438-47, 2013 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23902483